Xilio Therapeutics reported financial results for the quarter ended June 30, 2026, showing a net loss of $6.4 million compared to $15.8 million in the prior year period. Cash and cash equivalents stood at $136.0 million as of June 30, 2026, with management projecting a cash runway into the first quarter of 2028. The company announced FDA clearance for its IND application for XTX501, a bispecific PD-1/masked IL-2 therapy, and expects to initiate Phase 1 dosing in the second half of 2026. Additionally, Xilio is advancing IND-enabling studies for masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1, with IND submissions anticipated in the second half of 2027. Collaboration revenue increased to $18.7 million from $8.1 million year-over-year, driven by agreements with AbbVie and Gilead. Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for cancer treatment.

At its 2026 annual meeting on June 10, 2026, Xilio Therapeutics, Inc. elected Akintunde Bello, Ph.D., Daniel Curran, M.D., Robert Ross, M.D., and Yuan Xu, Ph.D., as Class II directors. To achieve board class balance, Dr. Curran resigned as a Class II director and was immediately re-appointed as a Class III director. Stockholders also ratified Ernst & Young LLP as the independent auditor for the 2026 fiscal year and approved the amendment and restatement of the 2021 Stock Incentive Plan to include prefunded warrants in the annual evergreen increase calculation. Xilio Therapeutics, Inc. is a biotechnology company focused on developing cancer therapeutics.